Medarex and GenPat77 Announce Therapeutic Antibody Co-Development Agreement
Complete the form below to unlock access to ALL audio articles.
Medarex, Inc. and GenPat77 Pharmacogenetics AG have entered into a collaborative agreement to develop fully human therapeutic antibody products.
The companies plan to use Medarex's UltiMAb Human Antibody Development System® to generate antibodies to disease targets provided by GenPat77.
Under the terms of the agreement, Medarex and GenPat77 plan to share product development and commercialization responsibilities on any antibody products resulting from this collaboration.
"We are pleased to have the opportunity to combine our fully human antibody technology with GenPat77's novel targets and to work together toward the development of potential new therapeutics for autoimmune diseases," said Donald L. Drakeman, President and CEO of Medarex.
Nalan Utku, CEO and President of GenPat77, adds, "We believe that Medarex's UltiMAb Human Antibody Development technology is an excellent solution for the generation of fully human antibodies against our therapeutic targets."
"We believe that we will have a successful collaboration with the Medarex team."
